BibbInstruments (BIBB.SL) Stock Price

BibbInstruments Price

CLOSED
0.38
​
Market closed

Revenue has compounded at 39.3% per year over the past 11 years to 401,000.00 SEK. Earnings per share have declined at 78.7% per year over the last 2 years. BibbInstruments's net margin stands at -3,643.4%, down from -1,729.5% several years earlier.

BibbInstruments stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BibbInstruments business model & stock analysis

BibbInstruments AB is a specialized medical technology enterprise headquartered in Lund, Sweden, operating within the health care sector. The company focuses on the development and marketing of advanced diagnostic instruments designed for the early detection of cancerous tumors. BibbInstruments went public on the Stockholm Stock Exchange on October 27, 2017, under the ticker symbol BIBB.SL, with the associated ISIN SE0010102095. Despite its technological focus, the organization maintains a lean operational structure, currently employing only four full-time staff members. The core of the company’s innovation lies in its proprietary technology platform known as EndoDrill. This platform utilizes a unique drill function that facilitates early cancer diagnosis, particularly within deep skin tissues and internal organs, offering a minimally invasive alternative to traditional biopsy methods. The product portfolio is diverse and tailored to specific medical needs across various bodily systems. It includes the EndoDrill GI Upper, which is engineered for stomach biopsies, and the EndoDrill GI Lower, designed for intestinal procedures. For respiratory diagnostics, the company offers the EndoDrill GI Lung for lung biopsies. Beyond diagnosis, the portfolio extends into therapeutic applications through the EndoDrill Therapy device, which allows for the passage of displacements in different organs to facilitate the placement of conductors, balloons, and stents for treatment purposes. Additionally, the EndoDrill Needle is available for breast biopsies, while the EndoDrill Model X serves multiple areas and is currently part of an independent research project. The company’s distribution strategy is primarily concentrated on Scandinavian countries, targeting hospitals equipped with endoscopy specialist centers and surgical wards. By focusing on these specific clinical environments, BibbInstruments aims to provide healthcare professionals with precise tools that enhance diagnostic accuracy and patient outcomes. The company’s website, https://www.bibbinstruments.com/, serves as the primary digital hub for information regarding its products and technological advancements. As a small but focused entity, BibbInstruments AB represents a niche player in the global medical device market, emphasizing innovation in early cancer detection through its specialized EndoDrill technology.

Frequently asked questions about BibbInstruments

Converted at the current exchange rate, the BibbInstruments share trades at 0.03 EUR (0.38 SEK).

The expected revenue of BibbInstruments is 1.20 M SEK. This figure is based on current financial data and reflects the company's business performance.

The profit cannot currently be calculated for BibbInstruments.

The P/E ratio cannot be calculated for BibbInstruments at the moment.

The price-to-sales ratio (P/S) of BibbInstruments is currently 12.76. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the BibbInstruments stock.

The Eulerpool Quality Score for BibbInstruments is 3/10.

The ISIN of BibbInstruments is SE0010102095. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of BibbInstruments is BIBB.SL. The ticker symbol is used to trade BibbInstruments shares on the stock exchange.

Fair ValueTerminal
0.31 SEK
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Health Care Equipment & Supplies
Number of shares
Employees
Revenue per Employee
100,250.00 SEK
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Sweden
Currency
SEK
Initial public offering
Oct 27, 2017
ISIN
SE0010102095
Cusip
W2R44L103
Market capitalization
15.32 M SEKMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
—
P/Ee 2027
—
P/Se
12.76
EV/EBIT
—
P/B Ratio
0.41
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-38.82 %
Last updated Oct 19, 2026, 7:20 PM

BibbInstruments Peer Group